Halozyme Therapeutics Inc’s recently made public that its Director Henderson Jeffrey William unloaded Company’s shares for reported $0.5 million on Jan 06 ’25. In the deal valued at $50.01 per share,10,000 shares were sold. As a result of this transaction, Henderson Jeffrey William now holds 43,611 shares worth roughly $2.44 million.
Then, JEFFREY HENDERSON bought 10,000 shares, generating $477,400 in total proceeds.
Before that, LaBarre Michael J. sold 10,000 shares. Halozyme Therapeutics Inc shares valued at $537,469 were divested by the SVP, CHIEF TECHNICAL OFFICER at a price of $53.75 per share. As a result of the transaction, LaBarre Michael J. now holds 173,756 shares, worth roughly $9.72 million.
Wells Fargo downgraded its Halozyme Therapeutics Inc [HALO] rating to an Equal weight from a an Overweight in a research note published on October 07, 2024; the price target was increased to $62 from $58. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid September from “an Overweight” to “a Neutral”. Piper Sandler also remained covering HALO and has decreased its forecast on June 07, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. TD Cowen started covering the stock on February 29, 2024. It rated HALO as “an Outperform”.
Price Performance Review of HALO
On Tuesday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock jump 2.08% to $55.94. Over the last five days, the stock has gained 3.32%. Halozyme Therapeutics Inc shares have risen nearly 17.00% since the year began. Nevertheless, the stocks have risen 60.15% over the past one year. While a 52-week high of $65.53 was reached on 01/21/25, a 52-week low of $33.15 was recorded on 01/03/25. SMA at 50 days reached $50.42, while 200 days put it at $51.12.
Levels Of Support And Resistance For HALO Stock
The 24-hour chart illustrates a support level at 55.08, which if violated will result in even more drops to 54.23. On the upside, there is a resistance level at 56.59. A further resistance level may holdings at 57.25. The Relative Strength Index (RSI) on the 14-day chart is 70.48, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.34, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.07%. Stochastics %K at 90.33% indicates the stock is a selling.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2024-12-31, growing by 0.94 million shares to a total of 9.5 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 8.57 million shares. There was a rise of 9.87%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 24, 2023 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $61 price target.
